Open AccessMetastatic Perivascular Epithelioid Cell Tumor Of The Kidney: A Case Report With Emphasis On Response To The Tyrosine-Kinase Inhibitor Sunitinib
Author(s) -
Rami Al-Azab,
Mohammed Alorjani,
Firas Sahawneh,
Sana Al-Sukhun
Publication year - 2019
Publication title -
research and reports in urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.506
H-Index - 20
ISSN - 2253-2447
DOI - 10.2147/rru.s226005
Subject(s) - sunitinib , medicine , tyrosine kinase inhibitor , renal cell carcinoma , tyrosine kinase , nephrectomy , pathological , adjuvant therapy , cancer research , pathology , kidney , oncology , cancer , receptor
Several case reports have provided most of the information available on perivascular epithelioid cell tumors, but with no consensus regarding diagnosis or treatment paradigms. Sunitinb is a VEGFR multitargeted tyrosine-kinase inhibitor that is regarded as a first-line treatment of clear cell-type metastatic renal-cell carcinoma after cytoreductive surgery. Our case was a 29-year-old male who presented with a metastatic left renal tumor and underwent left partial nephrectomy followed by adjuvant tyrosine kinase-inhibitor treatment. We report this case to present the peculiarity of this rare pathological variant, its clinical and diagnostic features, and challenges regarding treatment options, since the response of this rare tumor to adjuvant tyrosine kinase-inhibitor therapy has not been well described.